作为一种新的预测生物标志物和细胞癌的潜在治疗标,ESCO1
Yang Teng1, Sixiu Li2, Zhifang Zhang2
1Department of Oncology, the 4th Affiliated Hospital of Harbin Medical University (Songbei Branch), Harbin, Heilongjiang, China.
Tumori
|February 16, 2025
概括
在瘤中建立姐妹染色体凝聚N-乙转移酶1 (ESCO1) 的表达增加与细胞癌 (RCC) 患者的不良预后相关. 下调ESCO1抑制RCC细胞的增殖和迁移.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 建立姐妹染色体凝聚力N-乙转移酶1 (ESCO1) 对线粒分裂至关重要,并与膀和前列腺癌的进展有关.
- 在细胞癌 (RCC) 发病过程中ESCO1的作用及其作为生物标志物的潜力仍然未被探索.
研究的目的:
- 为了研究ESCO1下调对RCC细胞的影响.
- 评估ESCO1作为RCC患者的预后生物标志物.
主要方法:
- 对263名RCC患者的瘤样本进行了回顾性分析.
- 对ESCO1表达与患者生存数据的相关性.
- 评估ESCO1对RCC细胞增殖,迁移和亡的影响.
主要成果:
- 在脏瘤组织中,ESCO1显著过度表达.
- 较高的ESCO1表达与恶性瘤的增加和RCC的不良预后有关.
- 下调ESCO1降低了RCC细胞的增殖和迁移,抑制了G1阶段的进展.
结论:
- 在瘤中ESCO1表达升高可能作为RCC的宝贵预后生物标志物.
- 降低ESCO1水平会阻碍癌细胞的增殖和迁移,同时促进亡.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


